Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Series C generates $50mm for Enobia

Executive Summary

Enobia Pharma (developing drugs for bone disorders having no currently available treatment) brought in $50mm through its Series C round to returning shareholders OrbiMed Advisors, CTI Life Sciences Fund, Fonds de Solidarite FTQ, Desjardins Venture Capital, and Lothian Partners. The company will put the money towards ongoing Phase II trials of its lead enzyme replacement therapy ENB0040 for hypophosphatasia. Some funding will also support an undisclosed early-stage program. Enobia believes the money should last through the first half of 2011.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register